Background and core of therapy
Historically, the treatment of carbohydrate metabolism disorders has been associated with the use of insulin. However, direct administration of this hormone in pill form is impossible: it is completely destroyed in the gastrointestinal tract before reaching blood plasma. It is precisely this inability to be administered enterally that became the primary prerequisite for developing synthetic oral hypoglycemic agents.
The main indication for their prescription is uncomplicated type 2 diabetes mellitus (T2D). It is important to understand that oral agents are fundamentally different from exogenous insulin. They do not replace the hormone directly, but rather intervene in complex pathogenetic mechanisms of metabolism.
The basic chemical groups of these drugs include:
- Sulfonylureas.
- Biguanides.
- Tetrasaccharide derivatives.
- Thiazolidinediones.
- Meglitinides.
Pathophysiological rationale for treatment choice
Clinicians view type 2 diabetes mellitus as a heterogeneous (highly diverse) pathology. The choice of a specific drug depends on which pathogenetic mechanism predominates in the patient. Classically, two polar clinical variants of the disease course are distinguished.
Variant A: Elderly patients without obesity In this group, the underlying cause of the disease is insufficient production of the patient's own (endogenous) insulin. A state of absolute or relative hypoinsulinemia occurs. Therefore, the main therapeutic goal here is the pharmacological stimulation of insulin secretion (incretion) by pancreatic cells.
Variant B: Overweight individuals In this case, the picture is cardinally different: high levels of insulin (hyperinsulinemia) are recorded in the blood against the background of persistent hyperglycemia. This is a classic manifestation of metabolic syndrome (Syndrome X).
Its foundation is insulin resistance—the loss of sensitivity of peripheral tissue receptors to the hormone. A dangerous pathological cascade develops:
- Tissues stop responding to insulin.
- The body compensatorily increases hormone secretion.
- Hyperlipidemia, severe obesity, and cardiovascular disorders develop.
The therapeutic goal in this case is logical: it is necessary to overcome tissue resistance and increase cell sensitivity to insulin.
Classification by Mechanism of Action
In modern endocrinology, hypoglycemic agents are grouped strictly according to the link of pathogenesis they affect.
- Secretagogues (agents that stimulate endogenous insulin incretion). These drugs force the pancreas to secrete more hormone. They include sulfonylureas, incretin mimetics, and meglitinides (the latter are also called "glinides" or prandial glucose regulators).
- Sensitizers (agents that reduce insulin resistance). They increase tissue sensitivity to insulin, restoring their ability to adequately utilize glucose. This group includes biguanides and thiazolidinediones.
- Glucose absorption inhibitors. They act locally, blocking carbohydrate absorption directly in the intestine. Typical representatives are $\alpha$-glucosidase blockers.
- Replacement therapy agents. Insulin preparations are resorted to only in situations where the resources of the oral drug groups listed above are exhausted and they become ineffective.
Briefly: answers to topical questions
Which drugs belong to the secretagogue group?
The secretagogue group includes drugs whose mechanism of action is based on stimulating the incretion (release) of endogenous insulin by pancreatic beta cells. This group includes the following drug classes:
- Sulfonylureas—enhance insulin production (e.g., glibenclamide).
- Meglitinides—prandial glucose regulators, or "glinides" (e.g., nateglinide, repaglinide), providing a short-term insulin response.
- Incretin mimetics and their enhancers—include glucagon-like peptide-1 (GLP-1) receptor agonists and dipeptidyl peptidase-4 (DPP-4) inhibitors, such as gliptins (e.g., saxagliptin).
Which medications are included in the sensitizer group?
The insulin sensitizer group includes drugs that reduce insulin resistance and increase peripheral tissue sensitivity to this hormone. They include:
- Thiazolidinediones—insulin sensitizers (e.g., pioglitazone, rosiglitazone).
- Biguanides—drugs that reduce insulin resistance in muscle and adipose tissue (metformin is most commonly used).
Both groups reduce insulin resistance in muscle and adipose tissue and decrease hepatic glucose production.
What is the mechanism of action of glucose absorption inhibitors?
The mechanism of action of glucose absorption inhibitors consists of the competitive and reversible inhibition of enzymes in the small intestine. Sites of action (using acarbose as an example):
- Pancreatic $\alpha$-amylase—its suppression blocks the breakdown of dietary polysaccharides into disaccharides.
- Intestinal membrane-bound $\alpha$-glucosidase—its suppression blocks the breakdown of disaccharides into monosaccharides.
As a result, the formation of monosaccharides in the intestinal lumen is impaired, leading to a slowing and reduction of carbohydrate absorption from food into the systemic circulation.
Class and exam questions
Why can't you just take insulin pills for type 2 diabetes?
Insulin is degraded in the gastrointestinal tract when taken enterally. That is why synthetic drugs with completely different mechanisms of action were created for oral therapy.
What is the essence of metabolic syndrome (Syndrome X) in diabetes?
The syndrome is based on insulin resistance—the loss of tissue sensitivity to insulin. This causes compensatory hyperinsulinemia, which ultimately leads to obesity, hyperlipidemia, and cardiovascular disorders.
Which drug group is indicated for elderly patients without obesity?
Since they predominantly suffer from insufficient production of their own insulin, they are indicated for agents that stimulate its secretion (incretion)—the so-called secretagogues.
When to switch to insulin injections in type 2 diabetes?
Insulin preparations are prescribed as replacement therapy in cases where synthetic oral hypoglycemic agents cease to provide the desired effect.
What else to study on this topic
- Mechanism of action and pharmacokinetics of sulfonylureas
- Biguanides: effects on the liver and peripheral tissues
- Thiazolidinediones as insulin sensitizers
- Prandial glucose regulators (meglitinides) and their place in therapy
- Mechanism of intestinal $\alpha$-glucosidase blockade
- Principles of action of incretin mimetics
Master the entire topic in the «Pharmacology» course
This is a summary. The course covers everything tested in classes and exams.
- Complete study guide on "Oral Hypoglycemic Agents" and another 5,304 pages of the subject
- Assignments and quizzes after every topic — just like in a colloquium
- AI tutor answers questions on the topic anytime
- 116 video lessons on the subject
Other topics in the section "Hormone preparations, their synthetic substitutes, and antagonists"
Free video lessons: pharmacologyShort lessons with study notes — no registration required.
Prepared by WhiteCoat Pro faculty in accordance with the medical school curriculum. For educational purposes only.